Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions

Amir Eldar¹, Haim Rozenberg¹, Yael Diskin-Posner¹, Remo Rohs² and Zippora Shakked¹* ¹Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel ²Molecular and Computational Biology Program, University of Southern California, Los Angeles, CA 90089, USA

*To whom correspondence should be addressed. Tel: +972 8 934 2672; Fax: +972 8 934 6278; Email: <u>zippi.shakked@weizmann.ac.il</u>

Crystals	Protein concentration	Protein/DNA duplex ratio ²	Reservoir solution		
	(mg/ml)		Salt (mM)		PEG 3350 (%)
R273H (form I)	5		Mg-Formate	120	12
R273H (form II) ³	4	1:1.5	KCl	200	20
R273H/T284R	8.1		NaF	200	20
R273H/T284R-DNA	5	1:2.4	NH_4F	140	14
R273H/S240R	4		Na_2HPO_4	200	20
R273C	4		K-Acetate, KF	100,100	20
R273C/T284R	6		NH ₄ -Acetate	120	12
R273C/T284R-DNA	3.6	1:2	Li-Acetate	140	14
R273C/S240R-DNA	3.5	1:2.4	NH_4F	180	16

Supplementary Table S1. Crystallization conditions of R273-related mutants¹.

¹ In each case, 2μ l of protein or protein-DNA solution containing 20 mM sodium citrate pH 6.1, 150 mM NaCl, 10 μ M ZnCl2, and 10 mM DTT were mixed with 2μ l of the corresponding reservoir solution and equilibrated against 0.5 ml reservoir solution.

² DNA sequence c<u>GGGCATGCCCg</u>, consensus sequence underlined.

³ This crystal form was obtained from a solution of the protein/DNA complex.



Secondary structures of R273-related mutants. The structures were produced by ProCheck (1). Wild-type p53 structure is based on molecule C of PDB ID 2AC0.

Supplementary Figure S1

Supplementary Figure S2



Stereo view of six core-domain molecules of R273H (form II) spiraling around the crystallographic 6_1 axis. The molecules are linked by the second-type Zn atoms (shown as yellow spheres) and intermolecular interactions illustrated in Figure 2B.

Supplementary Figure S3



DNA binding sites in type I and type II complexes. Both binding sites are formed by the same DNA dodecamer: 5'-c<u>GGGCATGCCCg</u>-3', incorporating a decameric half-site (underlined).
(A) In type I complex, the two half-sites (highlighted by the colored background) are separated by a 2-bp spacer. (B) In type II complex, the two half-sites are contiguous. See description in the text.
(C) Nucleotide numbering is 1-12 going from the 5' to 3' direction for each strand.

Supplementary Figure S4



Close-up views of the mutation sites in the oncogenic single mutants and in the rescued double mutants compared to the same region of the wt protein bound to DNA. The DNA part in the views of the mutation sites was modeled by best molecular fitting of each mutant molecule onto the protein part of the wt core domain bound to DNA (PDB ID 2AC0). Except for R273H (form II) with one molecule in the crystallographic asymmetric unit (C), all other crystal structures contain two (E) or four (**B,D,F,G**) unique molecules superposed on each other. Similarly to Figure 5 (see text), these views reflects the long distances between the side chains of R273H and R273C to the DNA backbone (close to 4 and 6Å, respectively).

Supplementary Figure S5



A/T base pairs shown by type-II rescued complexes. R273H/T284R-DNA (A) and R273C/S240R-DNA (B), display the common Watson-Crick base pairs shown within their respective electron density maps (sigma-A weighted $2F_o$ - F_c at 1 σ level). This is in contrast to the Hoogsteen base pairs shown by the corresponding complexes of the same DNA targets with p53 core domains where R273 residues remain intact (2). See also discussion in text.

Supplementary References

- 1. Laskowski R. A., Macarthur M. W., Moss D. S., and Thornton J. M. (1993) ProCheck a Program to Check the Stereochemical Quality of Protein Structures *J. Appl. Crystallogr.*, **26**, 283-291.
- 2. Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B., and Shakked Z. (2010) Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs *Nat Struct Mol Biol*, **17**, 423-429.